Pegaptanib sodium

被引：70

作者：

Fine, SL

Martin, DF

Kirkpatrick, P

机构：

[1] Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Hlth Syst, Philadelphia, PA 19104 USA

[2] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2005年 / 4卷 / 03期

关键词：

D O I：

10.1038/nrd1677

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In December 2004, pegaptanib sodium (Macugen; Eyetech/Pfizer), which targets vascular endothelial growth factor, was approved by the US FDA for the treatment of neovascular age-related macular degeneration. As well as being the first anti-angiogenic agent to be approved for this common eye disorder, it is also the first approved therapeutic based on an RNA structure known as an aptamer.

引用

页码：187 / 188

页数：2

共 9 条

[1] VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].

AIELLO, LP ;

AVERY, RL ;

ARRIGG, PG ;

KEYT, BA ;

JAMPEL, HD ;

SHAH, ST ;

PASQUALE, LR ;

THIEME, H ;

IWAMOTO, MA ;

PARK, JE ;

NGUYEN, HV ;

AIELLO, LM ;

FERRARA, N ;

KING, GL .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487

[2] Ophthalmic drug discovery [J].

Clark, AF ;

Yorio, T .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (06) :448-459

[3]

Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477

[4] The biology of VEGF and its receptors [J].

Ferrara, N ;

Gerber, HP ;

LeCouter, J .

NATURE MEDICINE, 2003, 9 (06) :669-676

[5] Drug therapy: Age-related macular degeneration. [J].

Fine, SL ;

Berger, JW ;

Maguire, MG ;

Ho, AC .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (07) :483-492

[6] Pegaptanib for neovascular age-related macular degeneration [J].

Gragoudas, ES ;

Adamis, AP ;

Cunningham, ET ;

Feinsod, M ;

Guyer, DR .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) :2805-2816

[7] A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss - AREDS Report No. 8 [J].

Kassoff, A ;

Kassoff, J ;

Buehler, J ;

Eglow, M ;

Kaufman, F ;

Mehu, M ;

Kieval, S ;

Mairs, M ;

Graig, B ;

Quattrocchi, A ;

Jones, D ;

Locatelli, J ;

Ruby, A ;

Capone, A ;

Garretson, B ;

Hassan, T ;

Trese, MT ;

Williams, GA ;

Regan, V ;

Manatrey, P ;

Streasick, P ;

Szydlowski, L ;

McIver, F ;

Bridges, C ;

Stanley, C ;

Cumming, K ;

Lewis, B ;

Zajechowski, M ;

Margherio, RR ;

Cox, MS ;

Camille, J ;

Falk, R ;

Siedlak, P ;

Neubert, C ;

Klein, ML ;

Stout, JT ;

O'Malley, A ;

Lauer, AK ;

Robertson, JE ;

Wilson, DJ ;

Beardsley, C ;

Anderson, H ;

Wallace, P ;

Smith, G ;

Howard, S ;

Dreyer, RF ;

Ma, C ;

Chenoweth, RG ;

Zilis, JD ;

Johnson, M .

ARCHIVES OF OPHTHALMOLOGY, 2001, 119 (10) :1417-1436

[8] 2′-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165) -: Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain [J].

Ruckman, J ;

Green, LS ;

Beeson, J ;

Waugh, S ;

Gillette, WL ;

Henninger, DD ;

Claesson-Welsh, L ;

Janjic, N .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (32) :20556-20567

[9]

2004, FDA LABELLING INFORM

← 1 →